

**Freedom of Information Act 2000 - Request Reference FoI/23/468**  
**Rheumatology drug treatments**

**Information Requested:**

It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

**Response Detail:**

Please find below the figures for the numbers of patients treated by the Rheumatology department (for any condition) during the period 1.6.23 to 31.8.23.

- Abatacept [Orencia]: 58
- Adalimumab [Humira]: 25
- Adalimumab Biosimilars: 215
- Apremilast [Otezla]: 0
- Baricitinib [Olumiant]: 34
- Bimekizumab [Bimzelx]: 0
- Certolizumab [Cimzia]: 85
- Etanercept [Enbrel]: 25
- Etanercept Biosimilars: 179
- Filgotinib [Jyseleca]: 1
- Golimumab [Simponi]: 86
- Guselkumab [Tremfya]: 4
- Infliximab [Remicade]: 5
- Infliximab Biosimilars: 17
- Ixekizumab [Taltz]: 6
- Risankizumab [Skyrizi]: 0
- Rituximab [MabThera]: 1
- Rituximab Biosimilars: 27
- Sarilumab [Kevzara]: 16
- Secukinumab [Cosentyx]: 28
- Tocilizumab [Ro Actemra]: 107
- Tofacitinib [Xeljanz]: 6
- Upadacitinib [Rinvoq]: 11
- Ustekinumab [Stelara]: 13